Atypical Pneumonia (Mycoplasma pneumoniae)

Overview


Plain-Language Overview

Atypical Pneumonia (Mycoplasma pneumoniae) is a type of lung infection that affects the respiratory system, particularly the lungs. It is caused by a small bacterium called Mycoplasma pneumoniae that lacks a cell wall, making it different from typical bacteria. This infection often leads to symptoms like a persistent dry cough, mild fever, and fatigue, which can last for several weeks. Unlike typical pneumonia, it usually causes less severe symptoms but can still significantly impact breathing and daily activities. The illness spreads through respiratory droplets when an infected person coughs or sneezes. It mainly affects children and young adults but can occur at any age. Early recognition of symptoms is important for diagnosis and management.

Clinical Definition

Atypical Pneumonia (Mycoplasma pneumoniae) is a form of community-acquired pneumonia characterized by infection of the lung parenchyma caused by the bacterium Mycoplasma pneumoniae, which lacks a cell wall and is resistant to beta-lactam antibiotics. The pathogenesis involves attachment to respiratory epithelial cells via specialized adhesins, leading to inflammation and impaired mucociliary clearance. Clinically, it presents with a gradual onset of nonproductive cough, low-grade fever, headache, and malaise, often with extrapulmonary manifestations such as hemolytic anemia or rash. Radiographic findings typically show diffuse interstitial infiltrates rather than lobar consolidation. It is significant due to its atypical presentation, resistance to common antibiotics, and potential for outbreaks in close-contact settings like schools and military barracks.

Inciting Event

  • Inhalation of respiratory droplets containing Mycoplasma pneumoniae initiates infection.

  • Exposure to an infected individual during close prolonged contact triggers disease onset.

Latency Period

  • Symptoms typically develop after an incubation period of 1 to 4 weeks following exposure.

  • The gradual onset reflects the slow replication and immune response to the organism.

Diagnostic Delay

  • Initial symptoms are often nonspecific and mild, leading to misdiagnosis as viral upper respiratory infection.

  • Lack of rapid, widely available diagnostic tests delays confirmation.

  • Chest X-rays may show nonspecific interstitial infiltrates, which can be mistaken for other pneumonias.

Clinical Presentation


Signs & Symptoms

  • Gradual onset of dry cough and low-grade fever

  • Headache and malaise are common systemic symptoms

  • Sore throat and hoarseness may precede cough

  • Extrapulmonary manifestations include rash, hemolytic anemia, and neurologic symptoms

  • Chest discomfort without pleuritic pain

History of Present Illness

  • Gradual onset of dry cough, low-grade fever, and malaise over several days to weeks.

  • Associated symptoms include headache, sore throat, and myalgias.

  • Cough often becomes persistent and may be accompanied by wheezing or dyspnea.

  • Extrapulmonary symptoms such as rash or hemolytic anemia may develop later.

Past Medical History

  • History of recent upper respiratory tract infection may precede pneumonia symptoms.

  • Previous episodes of atypical pneumonia increase suspicion for recurrence.

  • Underlying chronic lung disease can worsen clinical course.

Family History

  • No significant familial genetic predisposition is associated with Mycoplasma pneumoniae infection.

  • Clusters of cases may occur in families due to shared environmental exposure.

Physical Exam Findings

  • Fever with generally mild respiratory distress

  • Diffuse crackles or rales on lung auscultation without focal consolidation

  • Pharyngeal erythema without exudate

  • Non-exudative conjunctivitis may be present

  • Relative bradycardia compared to fever

Diagnostic Workup


Diagnostic Criteria

Diagnosis is primarily clinical, supported by a history of gradual onset dry cough and systemic symptoms with diffuse interstitial infiltrates on chest X-ray. Confirmatory diagnosis relies on serologic testing detecting specific IgM antibodies against Mycoplasma pneumoniae or PCR assays identifying bacterial DNA from respiratory samples. Culture is rarely used due to slow growth. Cold agglutinin tests may be positive but lack specificity. Diagnosis requires exclusion of typical bacterial pathogens and correlation with clinical and radiographic findings.

Pathophysiology


Key Mechanisms

  • Adherence of Mycoplasma pneumoniae to respiratory epithelial cells via P1 adhesin causes ciliary dysfunction and epithelial injury.

  • Immune-mediated inflammation triggered by host response leads to interstitial pneumonia and systemic symptoms.

  • Production of hydrogen peroxide and superoxide radicals by the organism causes oxidative damage to respiratory epithelium.

  • Delayed hypersensitivity reactions contribute to extrapulmonary manifestations such as rash and hemolytic anemia.

InvolvementDetails
Organs

Lungs are the primary organs affected, with inflammation of the alveoli and interstitium causing atypical pneumonia symptoms.

Upper respiratory tract involvement may cause pharyngitis and tracheobronchitis as part of the clinical presentation.

Tissues

Respiratory epithelium is damaged by Mycoplasma pneumoniae adherence and immune-mediated injury, leading to impaired mucociliary clearance.

Alveolar tissue undergoes inflammation and edema, contributing to impaired gas exchange in atypical pneumonia.

Cells

Alveolar macrophages play a key role in phagocytosing Mycoplasma pneumoniae and initiating the immune response.

Neutrophils contribute to lung inflammation and tissue damage during the immune response to infection.

Epithelial cells of the respiratory tract are the primary site of Mycoplasma pneumoniae attachment and colonization.

Chemical Mediators

Interleukin-8 (IL-8) recruits neutrophils to the site of infection, amplifying lung inflammation.

Tumor necrosis factor-alpha (TNF-α) mediates systemic symptoms such as fever and malaise in atypical pneumonia.

Interferon-gamma (IFN-γ) enhances macrophage activation to control intracellular infection.

Treatments


Pharmacological Treatments

  • Macrolides (e.g., azithromycin)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit of Mycoplasma pneumoniae.

    • Side effects:
      • Gastrointestinal upset

      • QT prolongation

      • Hepatotoxicity

    • Clinical role:
      • First-line

  • Tetracyclines (e.g., doxycycline)

    • Mechanism:
      • Inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit, effective against Mycoplasma pneumoniae.

    • Side effects:
      • Photosensitivity

      • Tooth discoloration in children

      • Gastrointestinal upset

    • Clinical role:
      • First-line

  • Fluoroquinolones (e.g., levofloxacin)

    • Mechanism:
      • Inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Mycoplasma pneumoniae.

    • Side effects:
      • Tendonitis and tendon rupture

      • QT prolongation

      • Peripheral neuropathy

    • Clinical role:
      • Second-line

Non-pharmacological Treatments

  • Supportive care including adequate hydration and rest to aid recovery from atypical pneumonia.

  • Oxygen therapy for patients with hypoxemia to maintain adequate tissue oxygenation.

  • Use of antipyretics such as acetaminophen to control fever and alleviate discomfort.

Prevention


Pharmacological Prevention

  • No vaccine available; macrolide antibiotics used for early treatment to reduce transmission

  • Azithromycin prophylaxis in outbreak settings may be considered

  • No routine chemoprophylaxis recommended for general population

Non-pharmacological Prevention

  • Hand hygiene to reduce respiratory droplet spread

  • Avoidance of close contact with infected individuals during outbreaks

  • Respiratory etiquette including covering coughs and sneezes

  • Isolation of infected patients in communal settings to prevent transmission

Outcome & Complications


Complications

  • Autoimmune hemolytic anemia due to cold agglutinins

  • Stevens-Johnson syndrome as a rare hypersensitivity reaction

  • Guillain-Barré syndrome as a post-infectious neurologic complication

  • Secondary bacterial pneumonia from superinfection

Short-term Sequelae Long-term Sequelae
  • Persistent cough lasting weeks after acute illness

  • Fatigue and malaise during convalescence

  • Transient arthralgias or rash

  • Mild hypoxemia requiring supportive care

  • Rare development of bronchiectasis after severe or recurrent infections

  • Chronic cough due to airway hyperreactivity

  • Possible reactive airway disease exacerbation

  • No significant long-term pulmonary fibrosis typically

Differential Diagnoses


Atypical Pneumonia (Mycoplasma pneumoniae) versus Streptococcus pneumoniae pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Streptococcus pneumoniae pneumonia

Patchy, interstitial infiltrates on chest X-ray

Lobar consolidation on chest X-ray

No cell wall; not visible on Gram stain

Gram-positive diplococci visible on sputum Gram stain

Gradual onset with dry cough and low-grade fever

Abrupt onset with high fever and productive cough

Atypical Pneumonia (Mycoplasma pneumoniae) versus Chlamydophila pneumoniae pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Chlamydophila pneumoniae pneumonia

Cell wall–lacking bacterium detected by PCR or serology

Obligate intracellular bacterium detected by PCR or serology

Mild respiratory symptoms with extrapulmonary manifestations

Mild respiratory symptoms with prolonged cough

Positive serology or PCR for Mycoplasma pneumoniae

Positive serology for Chlamydophila-specific antibodies

Atypical Pneumonia (Mycoplasma pneumoniae) versus Legionella pneumophila pneumonia

Atypical Pneumonia (Mycoplasma pneumoniae)

Legionella pneumophila pneumonia

No specific water source exposure history

Recent exposure to contaminated water sources or air conditioning systems

Normal sodium and liver enzymes

Hyponatremia and elevated liver enzymes common

Negative urinary antigen test

Positive urinary antigen test for Legionella

Atypical Pneumonia (Mycoplasma pneumoniae) versus Viral pneumonia (e.g., Influenza virus)

Atypical Pneumonia (Mycoplasma pneumoniae)

Viral pneumonia (e.g., Influenza virus)

Gradual onset with primarily respiratory symptoms

Rapid onset with systemic symptoms like myalgia and headache

Patchy, localized interstitial infiltrates

Diffuse bilateral interstitial infiltrates

Negative viral tests; positive Mycoplasma PCR or serology

Positive viral PCR or rapid antigen test

Atypical Pneumonia (Mycoplasma pneumoniae) versus Tuberculosis

Atypical Pneumonia (Mycoplasma pneumoniae)

Tuberculosis

Subacute symptoms without systemic wasting

Chronic symptoms with weight loss, night sweats, and hemoptysis

Diffuse or patchy infiltrates without cavitation

Upper lobe cavitary lesions on chest X-ray

Negative acid-fast bacilli; positive Mycoplasma serology

Positive acid-fast bacilli smear or culture

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.